Law360, New York (December 02, 2009, 2:59 PM ET) -- A federal appellate court has affirmed the dismissal of a number of lawsuits from the multidistrict litigation alleging that Novartis Pharmaceutical Corp.’s bone cancer drugs Aredia and Zometa cause a condition involving jaw deterioration.
In two orders issued Nov. 24, a three-judge panel of the U.S. Court of Appeals for the Sixth Circuit affirmed the dismissal of eight lawsuits. The court said the claims were preempted by federal law and that some of the plaintiffs were pursuing their cases in the wrong jurisdiction.
In one order,...
6th Circ. Affirms Dismissals From Novartis MDL
To view the full article, take a free trial now.
